Scholarlink

Background <p>Biological sex influences cancer risk, molecular profiles, and clinical outcomes, yet its role in non-reproductive cancers remains underexplored.</p> Methods <p>This study investigated sex-based differences in somatic mutations, copy number alterations (CNAs), and overall survival (OS) across 34,782 patients from three global pan-cancer cohorts (TCGA, MSK MetTropism, and China OrigiMed), excluding reproductive cancers to minimize confounders. Sex-specific genetic alterations were assessed using Fisher's exact test, while OS differences were evaluated with Kaplan–Meier and Cox proportional hazards models.</p> Results <p> Incidence patterns revealed a strong male predominance in esophageal, liver, bladder, and head and neck cancers, whereas thyroid and gallbladder cancers were more common in females. OS analysis showed a consistent female advantage in both primary and metastatic cohorts, with males experiencing poorer OS in lung adenocarcinoma, glioblastoma, and pancreatic adenocarcinoma, although colorectal cancer with hepatic metastases favored males. Mutational profiling revealed that the <i>TP53</i>, <i>CDKN2A</i>, and <i>TTN</i> mutations were more frequent in males, while <i>EGFR</i>, <i>KRAS</i>, <i>BRAF</i>, and <i>PIK3CA</i> mutations occurred more often in females. Notably, <i>BRAF</i> and <i>EGFR</i> mutations were associated with better survival in females. CNAs analysis demonstrated male-biased amplifications, including <i>CCND1</i> and the FGF cluster in the China cohort, and <i>MYC</i>, <i>CCND1</i>, and <i>ERBB2</i> in the TCGA and MSK cohorts. In contrast, <i>MDM2</i> amplification was enriched in females in the China cohort.</p> Conclusion <p> These findings highlight both shared and population-specific molecular differences and underscore the importance of integrating sex as a biological variable in cancer genomics, biomarker development, and clinical trial design.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sex-based molecular and prognostic disparities in pan-cancer: an analysis across the global cohorts

  • 期刊论文

  • 发表日期：

    2025年11月17日

查看全文
  • Guruguhan Sivakumar,
  • Tapas Patra,
  • Durgadevi Veeraiyan,
  • Akhileshwar Namani

摘要

Background

Biological sex influences cancer risk, molecular profiles, and clinical outcomes, yet its role in non-reproductive cancers remains underexplored.

Methods

This study investigated sex-based differences in somatic mutations, copy number alterations (CNAs), and overall survival (OS) across 34,782 patients from three global pan-cancer cohorts (TCGA, MSK MetTropism, and China OrigiMed), excluding reproductive cancers to minimize confounders. Sex-specific genetic alterations were assessed using Fisher's exact test, while OS differences were evaluated with Kaplan–Meier and Cox proportional hazards models.

Results

Incidence patterns revealed a strong male predominance in esophageal, liver, bladder, and head and neck cancers, whereas thyroid and gallbladder cancers were more common in females. OS analysis showed a consistent female advantage in both primary and metastatic cohorts, with males experiencing poorer OS in lung adenocarcinoma, glioblastoma, and pancreatic adenocarcinoma, although colorectal cancer with hepatic metastases favored males. Mutational profiling revealed that the TP53, CDKN2A, and TTN mutations were more frequent in males, while EGFR, KRAS, BRAF, and PIK3CA mutations occurred more often in females. Notably, BRAF and EGFR mutations were associated with better survival in females. CNAs analysis demonstrated male-biased amplifications, including CCND1 and the FGF cluster in the China cohort, and MYC, CCND1, and ERBB2 in the TCGA and MSK cohorts. In contrast, MDM2 amplification was enriched in females in the China cohort.

Conclusion

These findings highlight both shared and population-specific molecular differences and underscore the importance of integrating sex as a biological variable in cancer genomics, biomarker development, and clinical trial design.